NCT02182219 2025-01-22
Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer
Boehringer Ingelheim
Phase 1 Completed
Clinical Trials
6 trialsNCT02835833 2018-07-10
Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
University of Alabama at Birmingham
Phase 1 Completed
NCT02182063 2017-12-28
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT01225887 2017-10-09
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT02278978 2015-05-12
BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
National Taiwan University Hospital
Phase 2 Unknown
NCT00706628 2015-01-15
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
Boehringer Ingelheim
Phase 2 Completed